Ratio Therapeutics Archives - Inside Precision Medicine

Inside Precision Medicine Ratio Nets Potential $750M Radioligand Cancer Deal with Novartis

Prostate cancer stages. ancerous cells, malignant tumor compresses urethra. Pathological disruption, genital reproductive system anatomy, bladder Oncological or Urological Disease,
bph, 3d render

News & Features

Ratio Nets Potential $750M Radioligand Cancer Deal with Novartis

November 19, 2024

Related Content

Cracking the Code of PARP Inhibitor Resistance in Advanced Prostate Cancer

Cracking the Code of PARP Inhibitor Resistance in Advanced Prostate Cancer

EZH2 Enzyme Linked to Drug Resistance and Tumor Growth in Prostate Cancer

EZH2 Enzyme Linked to Drug Resistance and Tumor Growth in Prostate Cancer

PTC Nets AADC Gene Therapy Approval: First Brain-Delivered Gene Therapy in U.S.

PTC Nets AADC Gene Therapy Approval: First Brain-Delivered Gene Therapy in U.S.

Combination Therapy for Small Cell Bladder and Prostate Cancer Shows Early Promise

Combination Therapy for Small Cell Bladder and Prostate Cancer Shows Early Promise